Self Thromboplastin - Prothrombin Time. A New Test in Hemorrhagic Syndromes and in the Control of Anticoagulant Therapy

Summary

1. A new method where the patients own plasma is clotted by the addition of his own whole blood hemolyzate is described. The hemolyzate here is the thromboplastinic source. The clotting time is recorded and called the Self Thromboplastin-Prothrombin time. This test gives abnormal results in cases with defective intrinsic prothrombin activation. The fact that it is abnormal in hypoproconvertinemia proves that it also reflects deficiencies in extrinsic activation of prothrombin.

2. This test is applicable for screening of hemorrhagic diseases concerning the second, third and fourth stages of coagulation. It can be used in the control of anticoagulant therapy with dicoumarol derivatives and heparin by means of a dilution curve.

• References

• 1 Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Pathol. 06: 23 1953;
• 2 Shinowara G. Y. Enzyme studies on human blood. XI. The isolation and characterization of thromboplastic cell and plasma components. J. Lab. clin. Med. 38: 11 1951;
• 3 Quick A. J, Georgatsos J. G, Hussey C. V. The clotting activity of human erythrocytes : theoretical and clinical implications. Amer. J. med. Sci. 228: 207 1954;
• 4 Quick A. J, Hussey V. C. Erythrocytin, a new clotting factor from erythrocytes, its value in the study of hemophilia. J. Lab. clin. Med. 46: 940 1955;
• 5 Quick A. J, Hickey M. E. Influence of erythrocytes on the coagulation of blood. Amer. J. med. Sci. 235: 51 1960;
• 6 Sirridge M. S, Bowman K. S, Allwin J. F. A simple whole blood screening test for disorders of thromboplastin generation. Amer. J. clin. Pathol. 37: 551 1962;
• 7 Ackroyd J. F. The function of factor VII. Brit. J. Haemat. 02: 397 1956;
• 8 Ulutin O. N. VII nci faktörün kan koagülasyonundaki rolü. Türk. Tip Cem. Mec. 23: 531 1957;
• 9 Ulin GollubSA, Likojf W. The complex pattern of response to coumarin drug therapy. The inadequacy of the prothrombin test as a guide to hypocoagulability. Amer. Heart J. 63: 591 1962;
• 10 Verstraete M, Clark P. A, Wright I. S. JJse of different tissue thromboplastins in the control of anticoagulant therapy. Circulation. 16: 213 1957;
• 11 Loeliger E. A. Schlechte Eigenschaft langwirkender Cumarine oder für deren Kontrolle ungeeignete Thrombokinase ? Schweiz, med. Wschr. 88: 639 1958;
• 12 Rodman T, Pastor B. H, Hoxter B. L. Problems encountered in the laboratory control of anticoagulant therapy with the one-stage determination of prothrombin complex activity. Amer. J. Med. 31: 555 1961;
• 13 Berkarda B, Derman U. Protrombin zamani tayininde inkübasyon müddetlerinin tesiri ve standardizasyonu. Tip Encümeni Ars. 10: 42 1962;